ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 9

Renal Protective Effect of Antiplatelet Therapy in Antiphospholipid Antibody-Positive Lupus Nephritis Patients without the Antiphospholipid Syndrome

Hironari Hanaoka1, Tomofumi Kiyokawa1, Harunobu Iida1, Yukiko Takakuwa1, Takahiro Okazaki2, Hidehiro Yamada3, Shoichi Ozaki4 and Kimito Kawahata1, 1Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 2Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 3Rheumatology, Seirei Yokohama Hospital, Yokohama, Japan, 4Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Antiphospholipid antibodies, lupus nephritis and renal disease

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Session Title: Antiphospholipid Syndrome Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Lupus nephritis (LN) class III or IV is associated with a poor prognosis for both patient and renal survival. Since antiphospholipid syndrome (APS) is reported to worsen the prognosis of LN, LN patients with APS should be treated with conventional immunosuppressive treatment plus antiplatelet or anticoagulation therapy according to the recommendations for LN management. However it has been unclear whether these therapies would benefit antiphospholipid antibodies (aPL)-positive LN patients not meeting the diagnostic criteria. Here, we evaluated the effect of antiplatelet therapy in addition to conventional immunosuppressive therapy for LN patients positive for aPL without definite APS.

Methods: Patients with biopsy-proven LN class III or IV who did not take hydroxychloriquine were retrospectively evaluated. We selected patients positive for anticardiolipin antibody (aCL) or lupus anticoagulant (LA) who did not meet the criteria for a diagnosis of APS. The patients were divided into two subgroups according to whether antiplatelet therapy was received. The cumulative complete renal response (CR) rate, relapse-free rate, and change in estimated glomerular filtration rate (eGFR) over 3 years after induction therapy were calculated.

Results: We identified 17 patients who received antiplatelet therapy and 21 who did not. Baseline clinicopathological characteristics and immunosuppressive therapy did not show a statistically significant difference between the two groups except for a significantly higher incidence of LN class IV in the treatment group (p = 0.03). There was no significant difference in cumulative CR rate, relapse-free rate, or eGFR change between these subgroups. However, when data on LA-positive patients were assessed, a significant improvement in eGFR was found (p = 0.04) in patients receiving antiplatelet therapy (Figure 1).

Conclusion: Addition of anti-platelet therapy was associated with an improvement of eGFR in LA-positive patients with LN class III or IV. There may be a wider indication for antiplatelet therapy in LN, in addition to its use in patients with a definite APS diagnosis.


Disclosure: H. Hanaoka, None; T. Kiyokawa, None; H. Iida, None; Y. Takakuwa, None; T. Okazaki, None; H. Yamada, None; S. Ozaki, None; K. Kawahata, None.

To cite this abstract in AMA style:

Hanaoka H, Kiyokawa T, Iida H, Takakuwa Y, Okazaki T, Yamada H, Ozaki S, Kawahata K. Renal Protective Effect of Antiplatelet Therapy in Antiphospholipid Antibody-Positive Lupus Nephritis Patients without the Antiphospholipid Syndrome [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/renal-protective-effect-of-antiplatelet-therapy-in-antiphospholipid-antibody-positive-lupus-nephritis-patients-without-the-antiphospholipid-syndrome/. Accessed May 19, 2022.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/renal-protective-effect-of-antiplatelet-therapy-in-antiphospholipid-antibody-positive-lupus-nephritis-patients-without-the-antiphospholipid-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.